Genetic disorders occur due to alterations in the primary genetic material—deoxyribonucleic acid (DNA)—of an organism.

CRISPR–Cas9-based therapies are widely investigated for their clinical applications. However, there are limitations ...

The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St.

Aurora Therapeutics, cofounded by Nobel Prize–winning scientist Jennifer Doudna, plans to use gene editing and a new FDA ...

In a new study, the researchers have shown that the CRISPR–Cas3 system can induce reliable, extensive deletions of the ...

CHANGE-seq-BE was developed to enable scientists to better understand base editors, an important class of CRISPR precise genome editors.

While researchers have long appreciated the enormous potential of genome editing to treat disease, applications of these technologies in humans have historically been limited by safety concerns. Even ...

Waking up this morning to news of the much-deserved Nobel Prize win for Emmanuelle Charpentier and Jennifer A. Doudna "for the development of a method for genome editing" confirms the importance of ...

Restricted access to genome-editing technologies poses serious challenges for countries like India that urgently need such ...